Regeneron Pharmaceuticals, Inc. (REGN) Stock: Price, Forecast & Analyst Target
Regeneron Pharmaceuticals, Inc. (REGN) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $945.53 (-1.28%), as of the Nov 18, 2026 trading session; market cap $97.8B. Expected results Jan 29, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Regeneron Pharmaceuticals, Inc. · REGN · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: Regeneron is a profitable biopharmaceutical manufacturer whose economics come from marketed medicines such as EYLEA, Dupixent and Libtayo, alongside collaboration revenue from partners. Regeneron’s key tension is whether its expanding portfolio and partner economics can support heavy research spending while preserving strong margins and cash conversion.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Regeneron Pharmaceuticals (REGN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 7 of the last 8 reports
- expected results Jan 29, 2027
- Altman Z 7.91 · Piotroski F 7
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $945.53 | |
| Change on the day | -1.28% | |
| 52-week range | $591.52–$991.73 | |
| Market capitalisation | $97.8B | — |
| Price / earnings (trailing) | 20.39 | |
| Shares traded on the day | 704.3K | |
| Beta (volatility vs the S&P 500) | 0.24 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Regeneron Pharmaceuticals (REGN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Regeneron Pharmaceuticals (REGN), and what does it report?
Short answer · as of
Regeneron discovers, develops, manufactures and commercializes treatments across eye disease, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious disease and rare disorders.
Research dated 2026-09-12.
Reported revenue is a hybrid of medicine sales and collaboration economics; collaboration revenue exceeds product revenue in the annual breakdown, so prescription demand alone does not explain changes in the top line.
What do the latest results show for Regeneron Pharmaceuticals (REGN)?
Research dated 2026-09-12.
The most recent reported period produced the highest revenue in the series shown, accompanied by a sharp sequential recovery in operating profit, net income and diluted earnings. Revenue and adjusted earnings also exceeded expectations, extending a run of favorable reported comparisons after an earlier shortfall.
Cash conversion moved differently: operating cash flow weakened despite the earnings recovery, while research spending remained near its recent peak. Management separately expects Sanofi collaboration revenue to rise after repayment of the development balance allows Regeneron to record its full share of collaboration profits; that is a prospective partner-accounting mechanism, not an explanation supplied for the latest profit increase.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $5.12B Oct 30, 2026
- Latest report · revenue estimate
- $4.58B Oct 30, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 30, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 30, 2026 | $5.12B | $4.58B | $20.0700 | $16.5100 |
| Jul 30, 2026 | $4.29B | $3.82B | $14.2900 | $10.1600 |
| Apr 29, 2026 | $3.61B | $3.48B | $9.4700 | $8.9100 |
| Jan 30, 2026 | $3.88B | $3.81B | $11.4400 | $10.7400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $3.75B | $1.46B | $13.62 (diluted) |
| Q4 FY2025 | $3.88B | $845M | $7.86 (diluted) |
| Q1 FY2026 | $3.61B | $727M | $6.75 (diluted) |
| Q2 FY2026 | $4.29B | $1.30B | $12.23 (diluted) |
What are the financial strengths and risks for Regeneron Pharmaceuticals (REGN)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash and short-term investments comfortably exceed total debt, and the broader pool including long-term investments provides substantially more financial capacity. Liquidity ratios are strong, leverage is modest, and operating cash flow has remained positive throughout the reported series.
The caution sits in the direction of cash conversion rather than solvency. Cash and short-term investments have declined across the reported window, recent operating cash flow softened, and research expense has climbed over the annual history. Weakness in medicine demand or collaboration economics would therefore meet a research program carrying a heavy cost base, pressuring margins and internally generated cash.
What should you watch next at Regeneron Pharmaceuticals (REGN)?
Short answer · as of
The next earnings report is expected on Jan 29, 2027.
Research dated 2026-09-12.
The Sanofi collaboration line is the immediate operational marker: it should reveal whether the completed development-balance repayment produces the revenue step-up management described. Product revenue should be read beside it, because growth driven by partner economics has a different meaning from broader demand for Regeneron’s medicines.
Cash conversion deserves equal attention. A stronger collaboration contribution accompanied by improving operating cash flow and stable margins would reinforce the latest earnings recovery; continued cash softness, rising research expense or margin compression would weaken that interpretation even if reported revenue meets the elevated expectation.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Regeneron Pharmaceuticals compare with its peers?
Short answer
Regeneron Pharmaceuticals's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Regeneron combines the economics of an established drug manufacturer with the research intensity of a biotechnology developer. Unlike a development-stage biotechnology company, it already produces substantial profit and operating cash from commercial medicines and collaborations; unlike a drugmaker whose revenue is dominated by direct product sales, Regeneron receives a larger annual contribution from collaboration revenue.
That mix makes partner profit-sharing unusually important to the reported result. The large investment pool and low leverage also give Regeneron more room to sustain research programs than a cash-constrained biotechnology peer, without removing the commercial risk attached to EYLEA, Dupixent, Libtayo and the wider portfolio.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $941.25 Nov 18, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| Regeneron Pharmaceuticals (REGN) — this page | $945.53 | $97.8B | 95 |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $400.84 Nov 18, 2026 | $86.6B | 88 5-pillar Nov 18, 2026 | |
| $85.57 Nov 18, 2026 | $34.8B | 87 5-pillar Nov 18, 2026 | |
| $39.43 Nov 18, 2026 | $174B | 87 5-pillar Nov 18, 2026 | |
| $348.28 Nov 18, 2026 | $66.5B | 86 5-pillar Nov 18, 2026 | |
| $285.38 Nov 18, 2026 | $75.2B | 78 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $756.00 – $1100.00
- Consensus target
- $904.60
- Median target
- $875.00
Consensus record · Captured .
Measured against a quoted price of $945.53 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 4, 2026
- Transactions
- 100
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 61
- Other transactions
- 39
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held REGN in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.35% | $80.33M | Added +106.4% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Regeneron Pharmaceuticals (REGN)?
Common Questions About REGN (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why can the Sanofi development balance change Regeneron collaboration revenue?
Repayment of the development balance allows Regeneron to recognize its full share of collaboration profits. Management therefore expects the Sanofi collaboration line to step up even without describing that change as direct product-sales growth.
Is EYLEA the whole Regeneron commercial story?
EYLEA is a major ophthalmology treatment, but Regeneron also markets medicines including Dupixent, Libtayo, Praluent, Kevzara, Inmazeb, ARCALYST and ZALTRAP. Collaboration revenue is larger than product revenue in the annual reporting split, further broadening the economics beyond EYLEA.
How does collaboration revenue differ from Regeneron medicine sales?
Medicine sales reflect Regeneron’s commercial products, while collaboration revenue reflects economics shared with partners under development and commercialization agreements. Because the collaboration line is larger in the annual mix, changes in partner profit-sharing can materially move reported revenue without matching a change in direct product demand.
Can Regeneron fund research across eye disease, inflammation and cancer from its own cash generation?
Regeneron remains profitable, generates positive operating cash flow and holds cash and investments well above debt, giving it substantial internal funding capacity. Research expense is rising and recent cash conversion weakened, so continued self-funding depends on commercial and collaboration profits keeping pace with the development program.
What is the REGN stock price today?
The last price recorded for Regeneron Pharmaceuticals, Inc. (REGN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the REGN price target?
The analyst consensus price target for Regeneron Pharmaceuticals, Inc. (REGN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 34 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold REGN
Funds in our ETF coverage that list REGN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.